DAX24.986 -0,2%Est506.293 -0,5%MSCI World4.343 -0,1%Top 10 Crypto8,0300 -0,7%Nas26.518 +1,9%Bitcoin54.953 +0,1%Euro1,1478 +0,2%Öl80,57 +1,7%Gold4.157 -1,3%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
SpaceX A42D4F SAP 716460 Infineon 623100 Volkswagen (VW) vz. 766403 Rheinmetall 703000 Siemens Energy ENER6Y NVIDIA 918422 BMW 519000 Deutsche Telekom 555750 Lufthansa 823212 Micron Technology 869020 Mercedes-Benz Group (ex Daimler) 710000 Allianz 840400 Deutsche Bank 514000 Microsoft 870747
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Großer Verfall: DAX geht unter 25.000 Punkten ins Wochenende -- Wall Street bleibt am Freitag geschlossen -- SpaceX mit Milliardenanleihe -- Rheinmetall, Lufthansa, ASML, Infineon, AIXTRON im Fokus
Top News
DAX in KW 25: Diese Aktien gehörten zu den Gewinnern und Verlierern DAX in KW 25: Diese Aktien gehörten zu den Gewinnern und Verlierern
Lufthansa-Aktie schwächer: Analyst sieht bei Ebit-Prognose Luft nach oben - aber Kursziel bleibt tief Lufthansa-Aktie schwächer: Analyst sieht bei Ebit-Prognose Luft nach oben - aber Kursziel bleibt tief
Suche...
Jetzt kostenlos
bei finanzen.net anmelden
Watchlists & Musterdepots Tools & integriertes Trading Newsletter, Trading-Desk uvm.
Schon einen Account? Anmelden
Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Amgen Aktie

Kaufen
Verkaufen
17.000,00 ARS -90,00 ARS -0,53 %
BUE
finanzen.net zero
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.166,61 Mrd. EUR

KGV28,23Div. Rendite1,53%
ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINARDEUT110665

Amgen Aktien News

DatumMeistgelesen
PR NewswireAMGEN TO PRESENT AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
PR NewswireAMGEN ACQUIRES DARK BLUE THERAPEUTICS, BOLSTERING ONCOLOGY PIPELINE
PR NewswireAMGEN TAKES ACTION WITH THE U.S. GOVERNMENT TO LOWER THE COST OF MEDICINES FOR AMERICAN PATIENTS
PR NewswireFDA APPROVES UPLIZNA® FOR ADULTS WITH GENERALIZED MYASTHENIA GRAVIS
PR NewswireAMGEN ANNOUNCES 2026 FIRST QUARTER DIVIDEND
PR NewswireAMGEN TO PRESENT AT CITI'S 2025 GLOBAL HEALTHCARE CONFERENCE
PR NewswireAMGEN TO PRESENT AT THE 8TH ANNUAL EVERCORE ISI HEALTHCONX CONFERENCE
PR NewswireFDA GRANTS FULL APPROVAL TO AMGEN'S IMDELLTRA® IN EXTENSIVE STAGE SMALL CELL LUNG CANCER
PR NewswireAMGEN'S REPATHA® CUTS RISK OF FIRST MAJOR ADVERSE CARDIOVASCULAR EVENTS BY 25% IN LANDMARK PHASE 3 VESALIUS-CV TRIAL
PR NewswireAMGEN ANNOUNCES 2025 FOURTH QUARTER DIVIDEND
PR NewswireAMGEN'S LANDMARK PHASE 3 REPATHA DATA TO BE PRESENTED AS LATE BREAKER AT THE AMERICAN HEART ASSOCIATION SCIENTIFIC SESSIONS 2025
PR NewswireAMGEN ANNOUNCES WEBCAST OF 2025 THIRD QUARTER FINANCIAL RESULTS
PR NewswireFDA APPROVES TEZSPIRE® FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
PR Newswire/C O R R E C T I O N -- Amgen/
PR NewswireAMGEN MAKES REPATHA® AVAILABLE THROUGH AMGENNOW, A DIRECT-TO-PATIENT PROGRAM IN THE U.S.
PR NewswireLANDMARK PHASE 3 TRIAL (VESALIUS-CV) MEETS PRIMARY ENDPOINTS IN A CARDIOVASCULAR PRIMARY PREVENTION STUDY OF 12,000 PATIENTS
PR NewswireAMGEN ANNOUNCES $650M EXPANSION OF U.S. MANUFACTURING, CREATING HUNDREDS OF NEW JOBS
PR NewswireAMGEN AND KYOWA KIRIN ANNOUNCE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 ASCEND LONG-TERM EXTENSION STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
PR NewswireAMGEN TO PRESENT AT THE MORGAN STANLEY 23RD ANNUAL GLOBAL HEALTHCARE CONFERENCE
PR NewswireAMGEN INVESTING MORE THAN HALF A BILLION DOLLARS IN NEW, STATE-OF-THE-ART CENTER FOR SCIENCE AND INNOVATION AT U.S. GLOBAL HEADQUARTERS
PR NewswireAMGEN TO PRESENT AT THE 2025 WELLS FARGO HEALTHCARE CONFERENCE
PR NewswireREPATHA® NOW INDICATED FOR ADULTS AT INCREASED RISK FOR MAJOR ADVERSE CARDIOVASCULAR EVENTS DUE TO UNCONTROLLED LDL-C
PR NewswireAMGEN REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS
PR NewswireAMGEN ANNOUNCES 2025 THIRD QUARTER DIVIDEND
PR NewswireAMGEN ANNOUNCES WEBCAST OF 2025 SECOND QUARTER FINANCIAL RESULTS
PR NewswireAMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR BEMARITUZUMAB IN FIBROBLAST GROWTH FACTOR RECEPTOR 2b (FGFR2b) POSITIVE FIRST-LINE GASTRIC CANCER
PR NewswireRESULTS FROM AMGEN'S PHASE 2 OBESITY STUDY OF MONTHLY MARITIDE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION 85TH SCIENTIFIC SESSIONS
PR NewswireAMGEN'S PHASE 2 MARITIDE DATA TO BE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION 85TH SCIENTIFIC SESSIONS
PR NewswireAMGEN AND FOOTBALL LEGEND BARRY SANDERS HIGHLIGHT DANGERS OF BAD CHOLESTEROL IN NEW DOCUMENTARY
PR NewswireAMGEN TO PRESENT AT GOLDMAN SACHS 46TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
PR NewswireIMDELLTRA® SIGNIFICANTLY REDUCED RISK OF DEATH BY 40% IN SMALL CELL LUNG CANCER PATIENTS
PR NewswireAMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE
PR NewswireAMGEN TO PRESENT AT THE 2025 RBC CAPITAL MARKETS GLOBAL HEALTHCARE CONFERENCE
PR NewswireAMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE
PR NewswireAMGEN REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS
PR NewswireCIBC introduces additional U.S. Canadian Depositary Receipts ("CDRs")
PR NewswireCIBC introduces additional U.S. Canadian Depositary Receipts ("CDRs")
PR NewswireAMGEN ANNOUNCES WEBCAST OF 2025 FIRST QUARTER FINANCIAL RESULTS
PR NewswireAMGEN ANNOUNCES $900 MILLION MANUFACTURING EXPANSION, CREATION OF 350 NEW JOBS IN OHIO
PR NewswireIMDELLTRA® DEMONSTRATED SUPERIOR OVERALL SURVIVAL IN SMALL CELL LUNG CANCER

Amgen News

Amgen News: auf dieser Seite finden Sie alle Amgen News und Nachrichten zur Amgen Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Amgen News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Amgen News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.